The model showed that among all molecular breast cancer types, HER2+ and ER/PR+ (oestrogen/progesterone receptor-positive) cancers have the highest hypoxia-related risk scores, while EP/PR-negative cancers present with more effective immune pathways, which in turn leads to enhanced response to therapies. This evidence concerns the gene ESR1 and breast carcinoma.